Business
Calidi Biotherapeutics Announces Shareholder Letter from CEO
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD. Dear Shareholders, 2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company’s lea
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TVVsA9n31LT1YQqkVdlDAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD.","length":355,"tagName":"p"},{"type":"text","content":"Dear Shareholders,","length":18,"tagName":"p"},{"type":"text","content":"2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company’s leadership, its focus and priorities, and in its balance sheet and operating expenses.","length":208,"tagName":"p"},{"type":"text","content":"I am thrilled to have joined as Chief Executive Officer in April 2025. I am honored to lead this incredible organization and work alongside a team of talented individuals who are committed to advancing our novel therapeutic approaches to oncology. In May 2025, we further expanded our team by appointing Dr. Guy Travis Clifton as our Chief Medical Officer, Advisor and Consultant, adding critical expertise in clinical program advancement and regulatory strategy.","length":463,"tagName":"p"},{"type":"text","content":"We have continued to advance our R&D pipeline. Of particular excitement is the rapid progress we have made with RedTail, the company’s approach to systemically delivering genetic medicines to metastatic sites in patients with advanced cancer using our proprietarily engineered enveloped virus. RedTail represents the culmination of over a decade of meticulous research and innovation at Calidi to create what we believe is the most advanced systemic virotherapy platform. Advancing this novel platform is the company’s main focus and priority.","length":5...